Daye, a London-based femtech startup founded by Valentina Milanova, has secured a new patent protecting the design and manufacturing process of its proprietary Organic Diagnostic & Menstrual Tampon. The development marks a major advancement in sustainable gynaecological care, blending innovation, performance, and environmental responsibility.
According to the company, the newly patented tampon offers superior performance compared to leading synthetic fibre alternatives. Made exclusively from organic, plastic-free materials, the product is designed to address common pain points associated with conventional menstrual care while paving the way for diagnostic applications using menstrual fluid.
The tampon incorporates several novel features: a protective sleeve that prevents fibre shedding, a dual-surface architecture to ensure rapid and uniform fluid absorption, and a cupped tip that expands evenly to minimise leakage and discomfort. Designed with scalability in mind, the tampon can also carry therapeutic coatings, making it a versatile solution in gynaecological health.
Fundraising and ongoing research
The patent announcement follows the successful conclusion of Daye’s Bright Friday campaign, which raised £11,114 in just 10 days. The funding has been channelled into critical areas of women’s health, many of which remain underfunded despite affecting a large portion of the population.
Among the active projects are the development of a non-hormonal, non-surgical treatment for endometriosis pain, research into the use of menstrual fluid for diagnosing heavy periods, and investigations into the links between endometriosis and excessive menstrual bleeding. Daye is also engaged in research surrounding gynaecological cancers, including ovarian and endometrial cancer.
Collaborating to close the gender health gap
As part of its broader mission to address the gender health gap, Daye has partnered with Wellbeing of Women, a UK charity that has played a leading role in women’s health research for over four decades.
The organisation has contributed to several key advancements in the field, including the introduction of ultrasound technology in prenatal care. This has enabled early detection of conditions such as spina bifida and enhanced monitoring in high-risk pregnancies.
Additionally, Wellbeing of Women supported research that helped establish the link between HPV infection and cervical cancer, a breakthrough that was instrumental in the creation of a national cervical screening programme and the rollout of the HPV vaccine. These efforts have led to a significant reduction in cervical cancer rates across the UK.
Daye continues to advocate for stronger support, better research funding, and inclusive healthcare solutions tailored to women and individuals assigned female at birth (AFAB). With its newly patented product, the company sets a new standard in menstrual and diagnostic care, combining science-led innovation with environmental responsibility and a sharp focus on user comfort.
